The inspiring & talented musician and composer 🎵🎵🎵 (in addition to Grade 10 student!), Mia Turakhia (who just happens to be the daughter of @leftbundle) presented today at #AHA26#ScientificSessions26 on the effect of music 🎶 exposure on preprocedural stress & anxiety 👏🏽👏🏽👏🏽
AF burden is increasingly being looked at as an outcome for clinical trials owing to the known limitations of time to event recurrence endpoints.
In the attached clinical trials workshop we critically examine the role of AF burden as an outcome for clinical trials of AF interventions, evaluating the evidence supporting AF burden as well as providing framework for an analytic strategy. We also delve into complementary metrics such as LEAF (longest episode of AF) and AF density.
@CardioUBC@DilawriCVI@VCHResearchevidence.nejm.org/doi/full/1…
Confusing recommendation for AF ablation in HFrEF with multiple consistent RCTs for ABL vs drugs yet LOE C! #2026ESC HF guidelines. Has there been a GDMT study in AF & HFrEF popn NOT inc substudies or secondary analysis? @drjohnm@nmarrouche@chris_sohns@escardio
Interesting piece. One question from the EP side: if interventional HF encompasses TEER, MCS, CCM, etc., shouldn’t CRT/CSP—one of the great success stories in HF—have a more central place? And if @HFSA@SCAI will co-own this emerging field, shouldn’t EP @HRSonline have a seat at the table?
Excellent statement on the journey so far and path forward toward interventional heart failure (IHF) as a discipline. Worth a read.
Link: sciencedirect.com/science/ar…
Title ⬇️
Day one at #HRX2026@experienceHRX is in the books! Looking forward to the next two days of this intentionally unconventional conference. Be there! #EPeeps
That's a wrap on Day 1 of HRX Live 2026! The Innovation Summit, our first Main Tent speaker, the opening pitch competition presentations — and we're just getting started. Stay tuned! More #HRX2026 coverage is coming your way, #EPeeps.
@MehakDhande@OliverMonfredi@Nashwa_Salem_
Bring your team to #WAFIB2027 for live cases, interactive debate, & practical insights spanning ablation, stroke prevention, PFA, LAAO, imaging, AI, & more.
$100 Off with Code AWARENESS: hubs.ly/Q04w-2ss0@nmarrouche@EPLabDigest
Important PVI-SHAM-AF trial—but interpretation matters. This was not ablation vs “nothing.” The sham arm included deep sedation, an invasive cath-lab procedure, intensive follow-up and, importantly, cardioversion when patients were in AF—itself an effective rhythm-control intervention.
Yet ablation still produced substantially better rhythm control (73% vs 52% freedom from AF).
With QoL assessed at only 6 months, are we measuring the effect of ablation—or comparing two active rhythm-control strategies?
I would be cautious concluding that ablation does not improve symptoms. The study may instead demonstrate how difficult it is to design a truly inert sham for AF.
#AFib#CatheterAblation#RhythmControl#PVI#ESCCongress@PrashSanders@drjohnm@chris_sohns@peterkistler3@DJ_Lakkireddy@DrRoderickTung@TinaBaykaner@DrJasonAndrade@SteffelJ@netta_doc@TulaneHeart
One of the #ESCCongress highlights:
#HOTLINE#LBCT
PVI-SHAM-AF
🫀262 patients (~1/2 women! 👏🏽)with symptomatic AF → ablation vs sham
🫀At 6 mo, AF-related QoL improved in BOTH groups, with no significant benefit from ablation (P=.36)
🫀But ablation improved freedom from AF: 73% vs 52%.
Better rhythm control ≠ necessarily better QoL @RoWachter
I love the sham trials!
Lancet: doi.org/10.1016/S0140-6736(2…
ENRICH-AF trial: In AF patients with prior ICH, edoxaban did not lower stroke or systemic embolism but increased major bleeding compared to non-anticoagulant therapy. Download slides here: clinicaltrialresults.org/wp-…
EPIDAURUS trial: In patients with AF and ACS, dual antithrombotic therapy with DOAC and intensified P2Y12-inhibition with prasugrel or ticagrelor for 1 month was associated with a higher bleeding risk without reducing ischemic events compared to triple antithrombotic therapy. Download slides here: clinicaltrialresults.org/wp-…